Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Healthcare - stethoscope-with-injection-protective-mask-lying-over-medical-chart-SBI-300904603
5 Breakout Biotech Stocks Leading the Russell 2000 Higher Barchart - Thu May 23, 12:52PM CDT

These small-cap biotech stocks are rallying hard in 2024, and still have room to keep leading the RUT higher.

JANX : 38.50 (-2.04%)
VKTX : 50.47 (-2.08%)
LBPH : 31.91 (+3.81%)
ARQT : 9.60 (+3.23%)
RNA : 37.21 (-4.10%)
Wall Street - shutterstock_2269106477
S&P Futures Higher After April CPI is Released Barchart - Wed May 15, 4:34AM CDT

June S&P 500 E-Mini futures (ESM24) are trending up +0.45% this morning after April's CPI report was released.

ESM24 : 5,471.89s (-0.09%)
SMCI : 847.00 (+1.17%)
ORCL : 144.38 (+0.77%)
SCHW : 74.13 (-0.03%)
PARA : 11.46 (+6.90%)
CSCO : 47.09 (-0.40%)
GRAB : 3.54 (+1.14%)
MNDY : 243.31 (+2.65%)
EXPN.LN : 3,687.000 (+0.71%)
MRK.D.DX : 151.100 (+0.70%)
NESTE.H.DX : 17.405 (-0.06%)
ARQT : 9.60 (+3.23%)
Wall Street - shutterstock_93231562
S&P Futures Slip as Investors Cautiously Await U.S. Big Bank Earnings, U.S. Rates Stay in Focus Barchart - Fri Oct 13, 2023

December S&P 500 futures (ESZ23) are trending down -0.24% this morning after three major U.S. benchmark indices closed lower on Thursday as hotter-than-expected U.S. inflation data bolstered bets on Federal...

ESZ23 : 4,694.27s (-0.58%)
DAL : 47.39 (+1.46%)
F : 12.87 (unch)
BYND : 6.83 (-1.30%)
FAST : 62.69 (-0.11%)
JPM : 208.69 (-0.07%)
WFC : 60.66 (-0.51%)
C : 64.46 (-0.34%)
BLK : 789.12 (unch)
PNC : 157.79 (-0.66%)
UNH : 489.89 (-1.68%)
DIM.FP : 151.950 (+1.88%)
Why Shares of Arcutis Biotherapeutics Fell This Week Motley Fool - Thu Sep 7, 2023

The company released phase 3 trial results for an atopic dermatitis cream.

ARQT : 9.60 (+3.23%)
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones PR Newswire - Tue Sep 5, 2023

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
ARQT : 9.60 (+3.23%)
Why Shares of Arcutis Biotherapeutics Jumped This Week Motley Fool - Fri Jun 9, 2023

The stock got a push when a British medical journal posted trials information on the company's lead product.

ARQT : 9.60 (+3.23%)
MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis PR Newswire - Thu Dec 1, 2022

/PRNewswire/ -- MyHealthTeam, creator of the largest and fastest-growing social networks for people living with chronic health conditions, today launched...

ARQT : 9.60 (+3.23%)
LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million PR Newswire - Thu Sep 8, 2022

/PRNewswire/ -- LifeArc today announced that its portfolio company DucentisBioTherapeutics, a preclinical-stage biotechnology company focused on developing...

ARQT : 9.60 (+3.23%)
NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING PR Newswire - Tue Aug 30, 2022

/PRNewswire/ -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) today announced the launch of an educational campaign designed to raise awareness about the...

ARQT : 9.60 (+3.23%)
Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older Globe Newswire - Wed Aug 10, 2022

Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies nationwideEffective, safe, and very...

ARQT : 9.60 (+3.23%)

Barchart Exclusives

Are These 3 Casino Stocks a Good Buy Now? Barchart - 6 minutes ago
Analysts rate all three casino stocks a “strong buy," and expect them to rally about 30% to 45%. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot